Evidence method
Level · gp.fundamentals.capex_revenue_ratio
6.74% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
WST · Mar 31, 2018
WEST PHARMACEUTICAL SERVICES INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000105770-18-000015General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
10.83% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.shares_outstanding
0.03% · CORE · VALID
Evidence method
Yoy · gp.fundamentals.revenue
7.22% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
51.89% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
32.33% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
12.85% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
2.31% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
0.82% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History39 statesSelf-history eligible
Mar 31, 201910/10 normalizedLevel 3Jun 30, 201910/10 normalizedLevel 3Sep 30, 201910/10 normalizedLevel 3Dec 31, 20198/8 normalizedLevel 3Mar 31, 20209/9 normalizedLevel 3Jun 30, 20209/9 normalizedLevel 3Sep 30, 20209/9 normalizedLevel 3Dec 31, 20209/9 normalizedLevel 3Mar 31, 20219/9 normalizedLevel 3Jun 30, 20219/9 normalizedLevel 3Sep 30, 20219/9 normalizedLevel 3Dec 31, 20219/9 normalizedLevel 3Mar 31, 20229/9 normalizedLevel 3Jun 30, 20229/9 normalizedLevel 3Sep 30, 20229/9 normalizedLevel 3Dec 31, 20229/9 normalizedLevel 3Mar 31, 20239/9 normalizedLevel 3Jun 30, 20239/9 normalizedLevel 3Sep 30, 20239/9 normalizedLevel 3Sep 30, 20269/9 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 8.18%
- Current
- 6.74%
- Delta
- -1.44%
- Previous
- 16.47%
- Current
- 10.83%
- Delta
- -5.64%
- Previous
- 5.96%
- Current
- 7.22%
- Delta
- 1.26%
- Previous
- 13.46%
- Current
- 51.89%
- Delta
- 38.43%
- Previous
- 32.06%
- Current
- 32.33%
- Delta
- 0.28%
- Previous
- 14.31%
- Current
- 12.85%
- Delta
- -1.47%
- Previous
- 2.45%
- Current
- 2.31%
- Delta
- -0.14%
- Previous
- 1.01%
- Current
- 0.82%
- Delta
- -0.19%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · WST Fundamental State →Analogous To · WST state analogue 2 →Has State · WEST PHARMACEUTICAL SERVICES INC →Transitioned To · WST Fundamental State →Transitioned To · WST CAPEX_INTENSITY_DECREASED →Transitioned To · WST CASH_GENERATION_DECREASED →Transitioned To · WST GROWTH_INCREASED →Transitioned To · WST INVENTORY_PRESSURE_INCREASED →Transitioned To · WST MARGIN_INCREASED →Transitioned To · WST PROFITABILITY_DECREASED →Transitioned To · WST R_AND_D_INTENSITY_DECREASED →Transitioned To · WST SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.